⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGM

FATE

Fate Therapeutics, Inc.

Healthcare · Biotechnology

2.44USD

-0.0600 (-2.40%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
Fiscal Year End12/2025
Last Quarter End06/2026 Q2
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 2.44
P/E—
Dvd Ind Yld—
P/B1.95
P/S46.1
Curr EV/T12M EBITDA-1.8
Mkt Cap (USD)0.3B
Curr EV (USD)0.2B
2)

Per Share Data

EPS T12M-1.05
DPS—
Bk Val Per Sh1.32
Rev/Sh0.05
Cash/Sh1.28
Curr Shares Out119.8M
FCF/Sh-0.88
3)

Cash Flow Analysis

P/CF-2.9
Curr P/FCF-2.8
CF/NI0.8
Dvd P/O0.0%
Cash Gen/Cash Reqd—
Csh Dvd Cov—
CFO/Sales-1570.0%
Eff Interest Rate12.2%
4)

Growth Potential

Dil EPS 1Y Gr29.9%
Cap 1Y Gr-35.0%
BPS 1Y Gr-37.8%
R&D To Sales1546.0%
Retention Rate100.0%
Rev 1Y Gr-51.2%
FCF 1Y Gr9.4%
Assets 1Y Gr-27.6%
5)

Profitability

EBITDA-0.1B
EBIT-0.1B
Operating Margin-2058.1%
Pretax Margin—
Net Margin-1941.1%
ROA-39.9%
ROE-60.7%
ROC—
Asset Turnover0.02
6)

Structure

Current Ratio4.85
Quick Ratio4.75
Debt/Assets9.0%
Debt/Com Eq15.3%
Net Debt/EBITDA0.07
Tot Debt/Capital13.2%
Gross Margin0.0%
EBIT/Int Exp-76.3

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.